CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) shares dropped 10.2% on Tuesday . The company traded as low as $3.70 and last traded at $3.77, approximately 1,154,961 shares were traded during trading. An increase of 406% from the average daily volume of 228,224 shares. The stock had previously closed at $4.20.

A number of equities analysts recently issued reports on CANF shares. HC Wainwright reissued a “positive” rating and issued a $5.00 price target (up from $3.00) on shares of CAN-FITE BIOPHA/S in a research note on Thursday, October 31st. Zacks Investment Research lowered shares of CAN-FITE BIOPHA/S from a “buy” rating to a “hold” rating in a report on Friday, October 4th.


Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

See Also: What are economic reports?

Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with's FREE daily email newsletter.